NCT07493135 2026-03-30
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
Clinical Trials
20 trialsNCT06663046 2026-01-20
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07336823 2026-01-13
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT05302648 2025-01-03
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Active not recruiting
NCT06209606 2024-12-17
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
Phase EARLY_PHASE1 Recruiting
NCT06732232 2024-12-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT05643248 2023-10-31
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
Nanexa AB
Phase EARLY_PHASE1 Completed
NCT06067581 2023-10-05
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT06045091 2023-09-21
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT03371420 2023-04-18
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT05652530 2022-12-15
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Shenzhen Pregene Biopharma Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05478343 2022-07-28
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04650724 2020-12-03
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Completed
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04186052 2019-12-04
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04156269 2019-11-12
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT03661554 2018-09-10
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Phase EARLY_PHASE1 Unknown
NCT03559764 2018-06-18
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown